Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

07/01/2021 | 04:15pm EDT

Krystal Biotech Inc. announced updated results from the Phase 1/2 clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) associated with mutations in the TGM1 gene. These data show that repeat doses of KB105 continue to be well tolerated with no adverse events and with no evidence of immune response, systemically or at the sites of application. Phenotypic improvement, based on the IGA scale, was observed at each KB105 dosing site at varying time points throughout the 30-day dosing period, with the maximum effect observed in the treatment areas that received the highest KB105 dose. These results build on previous data showing a dramatic increase in KB105-mediated TGM-1 expression and activity in 3 patients, which correlated with an improvement on the IGA scale after KB105 topical treatment, with or without pretreatment of the area through micro-needling. No drug-related adverse effects were reported. Initial Phase 2 Data: An adult subject, aged 63, was enrolled and four 100cm2 treatment areas were identified. Each treatment area was assigned to receive repeat doses of 4.0x109 PFU (n=2 treatment areas) or 1.0x1010 PFU (n=2 treatment areas). Each area was dosed on Day 1 and 3, after which dosing continued either every 3 days (n=2 treatment areas) or every 6 days (n=2 treatment areas) up to day 30. Treatment areas were clinically evaluated at pre- and post-KB105 application timepoints, using a 5-point IGA scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = very severe). Repeated topical doses of KB105 were well tolerated, and no drug-related adverse effects were reported. No vector shedding or systemic viral exposure was detected at any time point. Improvement on the IGA scale was observed in each treatment area, with the maximum effect observed in TA3 and TA4 that received the highest dose; at day 27, the investigator assigned an IGA score of 2, which was improved as compared to baseline score of 4 in each area. Variable 1-point improvements were observed at other time points and in the treatment areas that received the lowest dose. As in the Phase 1 portion of the trial, TGM1 turnover was observed to be variable but relatively rapid, and the observed IGA improvements were not sustained through day 60.


© S&P Capital IQ 2021
All news about KRYSTAL BIOTECH, INC.
09/16KRYSTAL BIOTECH : Guaranteed Maximum Price Amendment (Form 8-K)
PU
09/16KRYSTAL BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial St..
AQ
09/15Krystal Biotech Appoints Laurent Goux as General Manager of Europe
GL
09/09KRYSTAL BIOTECH : to Present Data on DEB and B-VEC at the DEBRA International Co..
AQ
09/07KRYSTAL BIOTECH : to Participate in H.C. Wainwright 23rd Annual Global Investmen..
AQ
08/19KRYSTAL BIOTECH : Regulation FD Disclosure (form 8-K/A)
AQ
08/09KRYSTAL BIOTECH, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
08/09KRYSTAL BIOTECH : Q2 Loss Widens
MT
08/09KRYSTAL BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
08/09Krystal Biotech, Inc. Reports Earnings Results for the Second Quarter Ended J..
CI
More news
Analyst Recommendations on KRYSTAL BIOTECH, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -84,8 M - -
Net cash 2021 339 M - -
P/E ratio 2021 -19,6x
Yield 2021 -
Capitalization 1 314 M 1 314 M -
EV / Sales 2021 -
EV / Sales 2022 3,34x
Nbr of Employees 75
Free-Float 75,4%
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 59,19 $
Average target price 98,43 $
Spread / Average Target 66,3%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
George Chen Manager-Information Technology & CSV
Trevor Parry Director-IP & Scientific Affairs
Brittani Agostini Manager-Clinical Operations
Court Freedman Senior Scientist
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.-1.35%1 314
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850